XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
B
B

Biogen

市场新闻

Reuters - 6天前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 6天前

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 1周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 1周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 1周前

Biogen Board Appoints Two New Independent Directors

BRIEF-Biogen Board Appoints Two New Independent Directors Sept 12 (Reuters) - Biogen Inc BIIB.O : BIOGEN BOARD APPOINTS TWO NEW INDEPENDENT DIRECTORS BIOGEN INC - APPOINTS LLOYD MINOR AND MENELAS PANGALOS AS INDEPENDENT DIRECTORS Source text for Eikon: ID:nGNX3jZhPK Further company coverage: BIIB.O
B
Reuters - 1周前

Bio-Thera Solutions And Biogen Publish Phase 3 Clinical Trial Data For TOFIDENCE

BRIEF-Bio-Thera Solutions And Biogen Publish Phase 3 Clinical Trial Data For TOFIDENCE Sept 11 (Reuters) - Bio-Thera Solutions Ltd 688177.SS : BIO-THERA SOLUTIONS AND BIOGEN PUBLISH PHASE 3 CLINICAL TRIAL DATA FOR TOFIDENCE™ BIO-THERA SOLUTIONS: COMPARABLE CLINICAL EFFICACY, SAFETY IN TREATMENT PERIOD 2 IS MAINTAINED AFTER SWITCH FROM REFERENCE T
B
Reuters - 1周前

Ionis Pharma falls on pricing $500 mln stock offering

BUZZ-Ionis Pharma falls on pricing $500 mln stock offering ** Ionis Pharmaceuticals IONS.O shares down 7.5% at $44.71 premarket after co secures equity raise ** Co late Mon announced 11.5 mln shares at $43.50 for ~$500.3 mln gross proceeds with Morgan Stanley and Goldman Sachs as jt bookrunners ** Offering price represents 10% discount to stock's last sale ** Co plans to use net proceeds to fund independent commercial launches, late-stage clinical/earlier pipeline programs, R&D, and for other pu
B
G
Reuters - 1周前

Ionis Pharma drops on $500 mln stock offering plans

BUZZ-Ionis Pharma drops on $500 mln stock offering plans ** Shares of Ionis Pharmaceuticals IONS.O down 7.6% at $44.64 post-market as co seeks equity raise ** Co announces $500 mln stock offering with Morgan Stanley and Goldman Sachs as jt bookrunners ** It plans to use net proceeds to fund independent commercial launches, late-stage clinical/earlier pipeline programs, R&D, and other general purposes ** Last week, Biogen BIIB.O /IONS announced higher dose Spinraza regimen met primary endpoint in
B
G
Reuters - 2周前

What to Watch in the Day Ahead - Wednesday, September 4

What to Watch in the Day Ahead - Wednesday, September 4 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT U.S. investors will look forward to the Labor Department's Job Openings and Labor Turnover Survey, or JOLTS report.
B
G
P
D
Reuters - 4周前

U.S. STOCKS NetEase, Wolfspeed, B. Riley

BUZZ-U.S. STOCKS ON THE MOVE-NetEase, Wolfspeed, B. Riley Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.
A
B
N
S
U
U
U
E
S
A
Reuters - 4周前

U.S. STOCKS Evogene, Stryker, Opera

BUZZ-U.S. STOCKS ON THE MOVE-Evogene, Stryker, Opera Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.
A
B
B
I
N
U
U
U
E
S
A
Reuters - 4周前

Biogen falls after new Alzheimer's drug deemed costly by UK pricing watchdog

BUZZ-Biogen falls after new Alzheimer's drug deemed costly by UK pricing watchdog ** Shares of Biogen BIIB.O fall 1.3% to $203.45 ** UK health regulator has approved BIIB and partner Eisai's 4523.T drug Leqembi, making it the first treatment for Alzheimer's disease licensed for use in the country ** However, the UK cost effectiveness body, the Nati
B
Reuters - 4周前

New Alzheimer's drug deemed too costly for UK's state-run health service

UPDATE 5-New Alzheimer's drug deemed too costly for UK's state-run health service Eisai-Biogen drug first treatment to slow Alzheimer's course UK draft guidance on cost a blow after slow take-up in U.S. Adds Biogen shares in paragraph 10 and analyst comment in paragraph 19 By Maggie Fick Aug 22 (Reuters) - Alzheimer's patients in Britain's state-run health service are unlikely to get access to Eisai 4523.T and Biogen's BIIB.O new Leqembi drug, after it was approved on Thursday by the country's r
B
Reuters - 4周前

NHS Says Awaiting Final Decision From NICE To Determine If Lecanemab Should Be Offered By NHS In England

BRIEF-NHS Says Awaiting Final Decision From NICE To Determine If Lecanemab Should Be Offered By NHS In England Aug 22 (Reuters) - NHS: NHS-AWAITS FINAL DECISION FROM NICE FOR CLINICAL BENEFITS, COST-EFFECTIVENESS OF LECANEMAB TO DETERMINE IF IT SHOULD BE OFFERED BY NHS IN ENGLAND
B
Reuters - 4周前

Biogen Says Eisai Working With NICE, SMC, NHS To Make Alzheimer's Drug Available As Soon As Possible

BRIEF-Biogen Says Eisai Working With NICE, SMC, NHS To Make Alzheimer's Drug Available As Soon As Possible Aug 22 (Reuters) - BIOGEN: EISAI WORKING WITH NICE, SMC AND NHS TO MAKE THIS MEDICINE AVAILABLE TO ELIGIBLE PEOPLE LIVING WITH EARLY AD AS SOON AS POSSIBLE Source text for Eikon: ID:nPn2g0Jvha Further company coverage: 4523.T
B
Reuters - 4周前

UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug

UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug Aug 22 (Reuters) - Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai 4523.T and Biogen's BIIB.O new Leqembi drug, after it was approved by the country's regulator but deemed too expensive for wide use on Thursday. Reporting by Maggie Fi
B
Reuters - 4周前

UK's MHRA Approves Eisai-Biogen's Alzheimer's drug

BRIEF-UK's MHRA Approves Eisai-Biogen's Alzheimer's drug Aug 22 (Reuters) - UK'S MHRA: LECANEMAB LICENSED FOR ADULT PATIENTS IN EARLY STAGES OF ALZHEIMER’S DISEASE UK'S MHRA: TOGETHER WITH CONDITIONS OF LICENCE APPROVAL, APPROPRIATE REGULATORY STANDARDS FOR LECANEMAB HAVE BEEN MET Further company coverage: 4523.T
B
Reuters - 4周前

UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS

BRIEF-UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS Aug 22 (Reuters) - UK'S NICE: UK'S NICE: BENEFITS OF ALZHEIMER’S TREATMENT LECANEMAB ARE TOO SMALL TO JUSTIFY COST TO THE NHS UK'S NICE: ISSUED DRAFT GUIDANCE FOR CONSULTATION NOT RECOMMENDING LECANEMAB FOR USE ON NHS AS IT IS NOT COST EFFECTIVE US
B
Reuters - 4周前

Alzheimer's drug from Eisai and Biogen to get approval in The Telegraph

MEDIA-Alzheimer's drug from Eisai and Biogen to get approval in UK - The Telegraph -- Source link: https://tinyurl.com/2xj9ac4e -- Note: Reuters has not verified this story and does not vouch for its accuracy
B
Reuters - 1个月前

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.
B
G
I
N

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。